Expanding the Promise of Gene Therapy to All Patients Living with Debilitating Diseases

Apertura is a biotechnology company opening opportunities for treating debilitating diseases with limited options. We are uniquely positioned to develop genetic medicines by simultaneously engineering AAV capsids, regulatory elements, and payloads to overcome current limitations in gene therapy. Apertura is committed to growing the field of gene therapy and believes that together we maximize our impact by working with corporate and academic collaborators, patients, and disease foundations. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure. building in New York City.

We are committed to inspiring the best in each of us to collectively achieve what hasn’t been done before. Join our team of driven scientists, engineers, and entrepreneurs to solve complex challenges in gene therapy.

The Key Founding Partners of Apertura Gene Therapy

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways. For more information, please visit deerfield.com.

The Broad Institute of MIT and Harvard is a research organization that seeks to better understand the roots of disease and narrow the gap between new biological insights and impact for patients. Our researchers are deeply collaborative, nimbly launching innovative projects at every scale, inventing new technologies, developing new therapeutics to advance into the clinic, and sharing our data and tools openly to enable breakthroughs anywhere. Visit broadinstitute.org to learn more.

Senior Director of Vector Engineering at the Stanley Center for Psychiatric Research at the Broad Institute

Ben Deverman is the Senior Director of Vector Engineering and an Institute Scientist at the Broad Institute of MIT and Harvard. Ben’s laboratory in the Stanley Center for Psychiatric Research at the Broad Institute develops and applies novel high-throughput screens and data-driven protein and genome engineering techniques to create more efficient and targeted AAV vectors to advance gene therapy and support scientific discovery. In prior work at the California Institute of Technology, Ben and colleagues identified numerous capsids, including AAV-PHP.B and an enhanced variant, AAV-PHP.eB, that made efficient brain-wide gene delivery possible for the first time. Ben earned a Ph.D. in Molecular Cell Biology from Washington University and was trained as a postdoc in neuroscience at the California Institute of Technology.